Business Context and Reporting Period
Aptevo Therapeutics Inc. filed this Form 8-K on August 6, 2018, to report the entry into a Material Definitive Agreement. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics and Debt Structure
This filing details amendments to the company's debt obligations rather than reporting operational financial results for a specific period. Key terms of the Amended and Restated Credit and Security Agreement include:
- Loan Amount: $20 million term loan.
- Lenders: Certain lenders with MidCap Financial Trust as agent.
- Maturity Date: Extended to February 1, 2023.
- Principal Amortization: Start date extended to February 1, 2020.
- Restricted Cash: Requirement reduced from $10 million to $5 million.
Material Changes Versus Prior Period
The filing outlines significant modifications to the original credit agreement:
- Extended Timeline: The maturity date and the commencement of principal payments have been pushed back by several years.
- Deferral Option: The company may further defer amortization payments to August 1, 2020, contingent upon achieving trailing twelve-month net commercial product revenues of $32 million by December 31, 2019, and maintaining that level quarterly thereafter.
- Liquidity Relief: The reduction in required restricted cash improves immediate liquidity availability.
- Covenant Revision: Minimum net commercial product revenue covenant levels were revised.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance or management commentary on future performance beyond the revenue targets required to trigger payment deferrals. The primary risk identified is the company's ability to meet the $32 million trailing twelve-month revenue threshold by the end of 2019 to secure the extended deferral of principal payments. The full text of the agreement is referenced for complete details.
Important Facts for Investor Verification
- Verify the company's current net commercial product revenue trajectory against the $32 million threshold required for the 2020 payment deferral.
- Confirm the impact of the reduced restricted cash requirement ($5 million) on the company's available working capital.
- Review the specific revised covenant levels for minimum net commercial product revenue in the full Amended Credit Agreement.
- Monitor upcoming Form 10-Q filings for the third quarter ended September 30, 2018, for complete financial and operational results.